Eric Bjerkholt insider trades: Mirum Pharmaceuticals (MIRM) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Eric reports to the SEC
and 5 more companies
Open-market buys and sales
38 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | MIRM | ↓ Sell | 9,943 | $98.37 | $978K | Direct | Sep 15, 2026 (1d) |
| Aug 11, 2026 | MIRM | ↓ Sell | 6,001 | $99.90 | $600K | Direct | Aug 12, 2026 (1d) |
| Jul 6, 2026 | MIRM | ↓ Sell | 5,000 | $122.25 | $611K | Direct | Jul 8, 2026 (2d) |
| Jun 9, 2026 | CERS | ↓ Sell | 20,454 | $2.60 | $53K | Direct | Jun 11, 2026 (2d) |
| Jun 8, 2026 | MIRM | ↓ Sell | 5,000 | $93.82 | $469K | Direct | Jun 9, 2026 (1d) |
| Mar 16, 2026 | MIRM | ↓ Sell | 7,287 | $91.98 | $670K | Direct | Mar 17, 2026 (1d) |
| Jan 26, 2026 | MIRM | ↓ Sell | 1,053 | $96.19 | $101K | Direct | Jan 27, 2026 (1d) |
| Jan 22, 2026 | MIRM | ↓ Sell | 1,421 | $93.33 | $133K | Direct | Jan 23, 2026 (1d) |
| Sep 12, 2025 | MIRM | ↓ Sell | 9,578 | $76.01 | $728K | Direct | Sep 12, 2025 (0d) |
| Dec 12, 2024 | CERS | ↓ Sell | 20,000 | $1.78 | $36K | Direct | Dec 16, 2024 (4d) |
| Mar 27, 2024 | MIRM | ↑ Buy | 2,000 | $24.80 | $50K | Direct | Mar 27, 2024 (0d) |
| Mar 18, 2024 | MIRM | ↑ Buy | 2,000 | $25.80 | $52K | Direct | Mar 18, 2024 (0d) |
| Dec 13, 2023 | CERS | ↑ Buy | 10,000 | $1.62 | $16K | Direct | Dec 13, 2023 (0d) |
| Sep 11, 2023 | MIRM | ↑ Buy | 10,000 | $29.65 | $296K | Direct | Sep 12, 2023 (1d) |
| Aug 21, 2023 | CERS | ↑ Buy | 10,000 | $1.72 | $17K | Direct | Aug 23, 2023 (2d) |
| May 31, 2023 | CALC | ↑ Buy | 255 | $4.14 | $1K | Direct | Jun 1, 2023 (1d) |
| May 23, 2023 | CALC | ↑ Buy | 500 | $3.27 | $2K | Direct | May 24, 2023 (1d) |
| May 23, 2023 | CERS | ↑ Buy | 5,000 | $2.00 | $10K | Direct | May 23, 2023 (0d) |
| May 19, 2023 | CALC | ↑ Buy | 200 | $2.65 | $530 | Direct | May 22, 2023 (3d) |
| May 18, 2023 | CALC | ↑ Buy | 1,300 | $2.70 | $4K | Direct | May 18, 2023 (0d) |
| Feb 10, 2023 | KDNY | ↓ Sell | 857 | $23.75 | $20K | Direct | Feb 15, 2023 (5d) |
| Jan 31, 2023 | KDNY | ↓ Sell | 2,891 | $24.68 | $71K | Direct | Feb 2, 2023 (2d) |
| Dec 1, 2022 | KDNY | ↓ Sell | 5,770 | $22.29 | $129K | Direct | Dec 2, 2022 (1d) |
| Feb 11, 2022 | KDNY | ↓ Sell | 895 | $12.74 | $11K | Direct | Feb 14, 2022 (3d) |
| Mar 12, 2020 | AIMT | ↑ Buy | 1,000 | $15.10 | $15K | Direct | Mar 12, 2020 (0d) |
| Mar 9, 2020 | AIMT | ↑ Buy | 1,000 | $18.97 | $19K | Direct | Mar 10, 2020 (1d) |
| Jan 29, 2020 | CERS | ↑ Buy | 20,000 | $4.15 | $83K | Direct | Feb 3, 2020 (5d) |
| Sep 18, 2019 | AIMT | ↑ Buy | 1,550 | $22.57 | $35K | Direct | Sep 20, 2019 (2d) |
| Jun 13, 2018 | AIMT | ↑ Buy | 1,600 | $30.41 | $49K | Direct | Jun 14, 2018 (1d) |
| Feb 26, 2018 | AIMT | ↑ Buy | 3,125 | $32.00 | $100K | Direct | Feb 26, 2018 (0d) |
| May 12, 2017 | AIMT | ↑ Buy | 5,000 | $19.84 | $99K | Direct | May 15, 2017 (3d) |
| May 19, 2016 | CORI | ↑ Buy | 12,500 | $3.65 | $46K | By the Bjerkholt Family Irrevocable Trus | May 20, 2016 (1d) |
| May 19, 2016 | CORI | ↑ Buy | 12,000 | $3.64 | $44K | By the Bjerkholt Children's Irrevocable | May 20, 2016 (1d) |
| Jul 24, 2015 | SNSS | ↓ Sell | 6,358 | $3.46 | $22K | Indirect | Jul 28, 2015 (4d) |
| Aug 27, 2014 | SNSS | ↓ Sell | 10,000 | $8.00 | $80K | Direct | Aug 29, 2014 (2d) |
| Oct 8, 2010 | SNSS | ↑ Buy | 100,000 | $0.31 | $31K | Indirect | Oct 8, 2010 (0d) |
| Jun 30, 2010 | SNSS | ↑ Buy | 238,243 | $0.28 | $66K | Indirect | Jul 1, 2010 (1d) |
| Mar 13, 2007 | SNSS | ↑ Buy | 3,000 | $4.30 | $13K | Direct | Mar 13, 2007 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other MIRM insiders
Open-market trades in the last 12 months
About Eric Bjerkholt's insider trades
Eric Bjerkholt is Chief Financial Officer at Mirum Pharmaceuticals (MIRM). Since Mar 13, 2007, Eric has reported 22 open-market purchases worth $1.0M and 16 sales worth $4.7M on SEC Form 4. In the last 12 months: 8 sales ($3.6M).
Their filings also include grants and awards (69 filings), option exercises (20 filings), shares withheld for taxes (9 filings), shares returned to the company (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MIRM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.